Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1865-8652
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan ; day:24 ; month:1 ; year:2023 ; pages:1-20
Advances in therapy ; (24.1.2023), 1-20

Creator
Ogura, Takashi
Inoue, Yoshikazu
Azuma, Arata
Homma, Sakae
Kondoh, Yasuhiro
Tanaka, Katsumi
Ochiai, Kaori
Sugiyama, Yukihiko
Nukiwa, Toshihiro
Contributor
SpringerLink (Online service)

DOI
10.1007/s12325-022-02411-y
URN
urn:nbn:de:101:1-2023033122130428845214
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 11:03 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Ogura, Takashi
  • Inoue, Yoshikazu
  • Azuma, Arata
  • Homma, Sakae
  • Kondoh, Yasuhiro
  • Tanaka, Katsumi
  • Ochiai, Kaori
  • Sugiyama, Yukihiko
  • Nukiwa, Toshihiro
  • SpringerLink (Online service)

Other Objects (12)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data

Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

Related objects